
## **Supplementary Material**

## Parkinson's Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort

Supplementary Table 1. The de	All cohort	Males	Females	EOPD	LOPD
Mean age of onset, (y)	$55.0 \pm 9.7$	$53.9 \pm 8.2$	$55.8 \pm 7.3$		
	00.0 - 9.1	p=0.002			
Mean age at examination, (y)	$62.2 \pm 9.0$	$61.2 \pm 9.5$	$63.0 \pm 8.5$		
ivican age at examination, (y)	$02.2 \pm 9.0$	1000000000000000000000000000000000000			
Mean disease duration, (y)	$7.1 \pm 5.2$	$7.2 \pm 17.1$	$10.8 \pm 7.1$		
ivican disease duration; (y)	$7.1 \pm 5.2$	$\frac{7.2 \pm 17.1}{p=0}$			
Mean UPDRS motor score	$34.9 \pm 18.2$	$\frac{p - 0.}{33.8 \pm 17.4}$	$35.3 \pm 17$	$39.5 \pm 19.4$	$32.8 \pm 17.2$
Mean OI DINS motor score	$54.7 \pm 10.2$	p=0.5		p=0.02	
Mean HYS	$2.3 \pm 0.8$	$\frac{p-0.2}{2.2 \pm 0.8}$	$\frac{3}{2.3 \pm 0.8}$	2.5±0.7	$\frac{2}{2.2\pm0.8}$
	$2.3 \pm 0.8$	$\frac{2.3 \pm 0.8}{p=0.16}$		p<0.01	
Onset before 50 years old, %	30.5% (302)	<u> </u>	27% (150)	p<0.0	1
(n)	30.376 (302)	30% (132)	2770 (130)		
Onset before 40 years old, %	7.6% (76)	9.9% (42)	5.7% (32)		
(n)	7.070 (70)	9.9% (42)	3.770 (32)		
M:F ratio, (total number)	1:1.3			1:0.99	1:1.5
MIF ratio, (total number)	(M-426,			(M-152,	(M-274,
	(WI-420, F- 564)			(M-132, F-150)	$(1v_{1}-2/4, F-414)$
FH, % (n)	4% (40)	4.7% (20)	3.5% (20)	7.6% (23)	2.3% (16)
				· · · · · ·	
Dyskinesia, % (n)	17.1% (170)	14.6% (62)	19.1% (108)	30.1% (91)	$\frac{11.4\%(79)}{00\%(72)}$
Dyskinesia plus fluctuations,	14.5% (144)	11.7% (50)	16.7% (94)	27.1% (82)	9% (62)
% (n)	500			500	500
Median dose of levodopa,	500			500	500
mg (range, mg)	(250-2500)				
On levodopatherapy, % (n)	68% (673)				
Levodopa monotherapy, %	34% (336)				
(n)	0.00/ (07)				
On Amantadine, % (n)	9.8% (97)				
<b>On DA, % (n)</b>	16.1% (159)				
On Rasagiline, % (n)	8.1% (80)				
On trihexyphenidyl, % (n)	6% (60)				

Supplementary Table 1. The demographic and clinical profile of the cohort in this study

UPDRS, Unified Parkinson's disease rating scale; HYS, Hoehn-Yahr stage; M:F ratio, male to female ratio; FH, family history; PD, Parkinson's disease; LOPD, late-onset Parkinson's disease; YOPD, early-onset Parkinson's disease, DA, dopamine agonists



**Supplementary Figure 1.** The gender distribution for Parkinson's disease onset in the age of decades. The figure shows that the high pick for Parkinson's disease onset for both genders in this study was between 51-60 years old. Vertical axis – the absolute number of patients, horizontal axis – decades for age.